Compare AbbVie Inc (ABBV) vs Clorox Co (CLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Clorox Co — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while Clorox Co trades at $94.88 (market cap $11.78B). The key difference: AbbVie Inc is far larger — about 38.2× Clorox Co's market cap, and Clorox Co pays the higher dividend (5.09%). Which is the better fit depends on your goals.
| ABBV | CLX | |
|---|---|---|
Market Cap | $449.91B | $11.78B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $131.43 |
52-Week Low | $184.85 | $86.12 |
Enterprise Value | $513.38B | $15.08B |
Dividend Yield | 2.72% | 5.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
CLX trades at $97.41, up 0.15% on the day, with a neutral technical signal and key support at $96. The company reported Q1 2026 EPS of $1.64, beating expectations, and maintains strong profitability with an 11.18% net margin. Recent news highlights a simplified operating structure and CEO transition, while analyst consensus is a $103.38 price target with a hold-heavy rating distribution.
The outlook is mixed: solid fundamentals and a nearly 5% dividend yield support income investors, but high debt levels and competitive pressures pose risks. Upside depends on execution of new growth initiatives under incoming leadership, with current valuation appearing reasonable relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
